Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

The phases of leukemia treatment

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

The word leukemia covers diseases that are treated completely differently. One may need to start chemotherapy the day it is diagnosed; another may need nothing at all for years.

What follows is the map. Which route applies to you depends on the exact subtype and its genetics, which is why the first thing worth asking is the full name of what you have.

Related pages: Leukemia (blood cancer)

The bottom line

What we know
  • Remission is not the same as cure, which is why consolidation follows induction.
  • Early treatment of asymptomatic chronic lymphocytic leukemia has not been shown to improve survival.
  • Tyrosine kinase inhibitors turned chronic myeloid leukemia into a manageable long-term condition.
  • Measurable residual disease testing detects leukemia far below the level a microscope can see.
What is still open
  • Which patients can safely stop a tyrosine kinase inhibitor after deep remission, which trials are still defining.
  • How far MRD results should drive treatment decisions in each subtype.

The story, step by step

  1. 1. Induction ()
  2. 2. After remission ()
  3. 3. Chronic leukemias ()
  4. 4. Transplant ()
  5. 5. MRD ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Getting to remission

Review of many studies

What happens

The first and most intensive phase in acute leukemia.

What the research shows

  • Induction aims to clear leukemic blasts from the marrow and restore normal blood production. For acute leukemia it usually begins within days of diagnosis.
  • It typically means three to six weeks in hospital, because the treatment wipes out normal marrow alongside the leukemia and the recovery period has to be supported with transfusions and antibiotics.
  • Remission means no leukemia visible under the microscope, usually under 5 percent blasts, with blood counts recovering. It is the goal, and it is not the end.
  • Tumour lysis syndrome, from the rapid breakdown of leukemia cells, is anticipated with fluids and with allopurinol or rasburicase.
  • Acute promyelocytic leukemia is a distinct case: it is treated with all-trans retinoic acid and arsenic trioxide rather than standard chemotherapy, and is now among the most curable leukemias, though it is a medical emergency at presentation because of bleeding risk.
  • Older or less fit patients increasingly receive lower-intensity regimens, such as a hypomethylating agent with venetoclax, which has changed what is possible for people who could not tolerate intensive induction.

Why it matters

Nearly all of the hardest weeks are in this phase, and most of what the living-with pages describe applies here most acutely.

What's still uncertain

  • Who benefits from intensive versus lower-intensity induction, which is an active question as the lower-intensity options improve.

Read more

Next: After remission

Part 2 of 5

Consolidation and maintenance

Review of many studies

What happens

Why treatment continues when the leukemia cannot be seen.

What the research shows

  • Remission by microscope still leaves leukemia cells behind in numbers far too small to see. Without further treatment, they regrow in most people.
  • Consolidation is further cycles of chemotherapy, sometimes with targeted agents, aimed at those remaining cells.
  • Maintenance, used especially in acute lymphoblastic leukemia, is lower-intensity treatment taken for two to three years, often as tablets at home.
  • Maintenance is where adherence becomes the main clinical issue, and studies have found that missed doses are associated with relapse. It is also the phase where people feel well and the reason for the tablets feels least obvious.
  • In ALL, treatment also targets the central nervous system, because leukemia cells can hide there where most chemotherapy does not reach. That means injections into the spinal fluid.
  • Whether a transplant is recommended is usually decided during or after consolidation, based on the genetics of the leukemia and the response.

Why it matters

The gap between feeling better and being finished is the hardest part of this phase to live with, and it is the reason the phase exists.

What's still uncertain

  • Whether maintenance duration can be shortened for people with excellent MRD responses.

Read more

Next: Chronic leukemias

Part 3 of 5

Tablets, and the case for waiting

Review of many studies

What happens

A completely different shape of treatment.

What the research shows

  • Chronic myeloid leukemia is driven by a single fusion gene, BCR-ABL1. Tyrosine kinase inhibitors such as imatinib block its product directly, and they changed CML from a fatal disease into one where life expectancy approaches normal.
  • They are usually taken indefinitely, with blood tests tracking the BCR-ABL1 level. Some people in sustained deep remission can attempt treatment-free remission under close monitoring, and about half stay in remission; the rest restart and respond again.
  • Chronic lymphocytic leukemia is often diagnosed from a routine blood test in someone with no symptoms. Multiple trials have shown that treating early does not improve survival, so observation with regular counts is standard until there is a reason to treat.
  • Reasons to treat CLL include falling blood counts, large or painful lymph nodes, an enlarged spleen, recurrent infections, or symptoms such as weight loss and night sweats.
  • When CLL is treated, the modern options are targeted: BTK inhibitors such as ibrutinib and acalabrutinib, and venetoclax, often with an antibody. Chemotherapy is now rarely first-line.
  • Watchful waiting is genuinely hard psychologically. Knowing that it rests on trial evidence rather than rationing helps some people, and it is a reasonable thing to ask your haematologist to explain.

Why it matters

These diseases are managed like chronic conditions. The daily work is adherence, side effects and regular monitoring rather than hospital admissions.

What's still uncertain

  • Which patients can safely stop a TKI, and for how long remission lasts, which long-term follow-up is still defining.

Read more

Next: Transplant

Part 4 of 5

What it involves, and who it is for

Review of many studies

What happens

The most intensive option, and the only one that replaces the marrow.

What the research shows

  • An allogeneic transplant replaces your blood-forming system with a donor's. High-dose chemotherapy, with or without radiation, clears the marrow, then donor stem cells are infused.
  • Engraftment, when the new cells begin producing blood, takes about two to four weeks, spent with almost no immune system.
  • Much of the benefit comes from the donor immune system recognizing and attacking residual leukemia, the graft-versus-leukemia effect.
  • The same mechanism causes graft-versus-host disease, where donor immune cells attack the recipient's tissues. Acute GvHD affects skin, gut and liver; chronic GvHD can affect many organs and persist for years.
  • Immunosuppressive medicines are taken for months or longer afterwards, and the immune system takes a year or more to rebuild. A full revaccination schedule is needed.
  • Reduced-intensity conditioning has made transplant possible for older patients who could not tolerate full conditioning.
  • Donors can be siblings, matched unrelated donors from registries, half-matched family members, or umbilical cord blood. Registry representation is uneven, and patients from some ethnic backgrounds have a harder time finding a match.

Why it matters

Transplant is offered when the risk of relapse without it outweighs its own substantial risks, which is a calculation specific to the leukemia's genetics and the person's fitness.

What's still uncertain

  • How to prevent chronic graft-versus-host disease without losing the graft-versus-leukemia effect, which is the central problem of the field.

Read more

Next: MRD

Part 5 of 5

Measuring what the microscope cannot see

Review of many studies

What happens

The testing that increasingly drives decisions.

What the research shows

  • Measurable residual disease testing uses flow cytometry or molecular methods to detect leukemia cells at levels far below the microscope's limit, often one cell in ten thousand or better.
  • MRD status after induction is one of the strongest predictors of relapse in several leukemias, often stronger than the features present at diagnosis.
  • It is used to decide whether to intensify treatment, whether to proceed to transplant, and in trials, whether treatment can be de-escalated.
  • In CML the equivalent is the BCR-ABL1 transcript level, reported on an international scale, which is what the terms major molecular response and deep molecular response refer to.
  • A positive MRD result does not mean treatment failed. It means the risk profile has changed and the plan may change with it.
  • Methods and thresholds differ between laboratories and between leukemia types, which is why results are interpreted by your team rather than compared with someone else's.

Why it matters

This is the main reason leukemia treatment has become more individualized over the last decade: the same remission can now be graded.

What's still uncertain

  • How far treatment should be guided by MRD rather than by disease features at diagnosis, which differs by subtype and is still being settled.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.